Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,371,580 papers from all fields of science
Search
Sign In
Create Free Account
FREM1 gene
Known as:
CHROMOSOME 9 OPEN READING FRAME 154
, C9orf143
, C9ORF154
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Frem1 protein, mouse
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
187 The Inflammatory Phenotype of the Tilrr Knockout Mouse - Mechanisms Undelying Reduced Responses to Vascular Injury
Emer Murphy
,
A. Samokhin
,
S. Francis
,
Susannah Bowskill
,
E. Qwarnstrom
Heart
2014
Corpus ID: 76380757
Background TILRR, an IL-1R1 co-receptor, is a strong amplifier of IL-1-induced inflammatory and anti-apoptotic signals controlled…
Expand
2014
2014
Development of monoclonal antibodies to interrogate functional domains and isoforms of FREM1 protein.
Xin Yong Yuan
,
L. R. Liu
,
+5 authors
Ma Luo
Monoclonal antibodies in immunodiagnosis and…
2014
Corpus ID: 196535880
FREM1 was first identified as an extracellular matrix protein that is essential for the formation of the epithelial basement…
Expand
2012
2012
18 TILRR Functional Mutants Selectively Inhibit Inflammatory and Anti-Apoptotic Responses
M. Neilan
,
Xiao Zhang
,
+4 authors
E. Qwarnstrom
Heart
2012
Corpus ID: 76019594
Toll-like and IL-1 receptors control inflammatory responses. TILRR (Toll-like IL-1 Receptor Regulator), is an IL-1 co-receptor…
Expand
2011
2011
14 The role of TILRR in vascular cell inflammation and development of atherosclerosis
M. Neilan
,
J. Boyle
,
A. Lawrie
,
S. Francis
,
D. Haskard
,
E. Qwarnstrom
Heart
2011
Corpus ID: 73000193
Inflammatory responses are induced by members of the Toll-like and Interleukin-1 receptor family. We have identified an IL-1RI…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE